Helius Medical Technologies to Present at LD Micro Invitational XIII 2023
Helius Medical Technologies (NASDAQ: HSDT), a neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, has announced its participation in the LD Micro Invitational XIII 2023. The event will take place at the Luxe Sunset Boulevard Hotel in California.
President and CEO Dane Andreeff, along with CFO Jeff Mathiesen, will represent Helius at the conference. Their presentation is scheduled for Wednesday, June 7, 2023, at 4:00 PM PT. Interested parties can access the webcast through the provided link.
Investors and attendees wishing to arrange one-on-one meetings with Helius management are encouraged to contact LD Micro directly. This event provides an opportunity for Helius to showcase its innovative approach to neuromodulation therapy and engage with potential investors.
Helius Medical Technologies (NASDAQ: HSDT), una società di neurotecnologia specializzata nella neuromodulazione terapeutica per deficit di equilibrio e deambulazione, ha annunciato la sua partecipazione all'LD Micro Invitational XIII 2023. L'evento si svolgerà presso il Luxe Sunset Boulevard Hotel in California.
Il presidente e CEO Dane Andreeff, insieme al CFO Jeff Mathiesen, rappresenteranno Helius alla conferenza. La loro presentazione è programmata per mercoledì 7 giugno 2023, alle 16:00 PT. Le parti interessate possono accedere al webcast tramite il link fornito.
Gli investitori e i partecipanti che desiderano organizzare incontri individuali con il management di Helius sono incoraggiati a contattare direttamente LD Micro. Questo evento offre un'opportunità per Helius di mostrare il suo approccio innovativo alla terapia di neuromodulazione e interagire con potenziali investitori.
Helius Medical Technologies (NASDAQ: HSDT), una empresa de neurotecnología que se especializa en la neuromodulación terapéutica para déficits de equilibrio y marcha, ha anunciado su participación en el LD Micro Invitational XIII 2023. El evento se llevará a cabo en el Luxe Sunset Boulevard Hotel en California.
El presidente y CEO Dane Andreeff, junto con el CFO Jeff Mathiesen, representarán a Helius en la conferencia. Su presentación está programada para miércoles 7 de junio de 2023, a las 4:00 PM PT. Las partes interesadas pueden acceder a la transmisión web a través del enlace proporcionado.
Los inversionistas y asistentes que deseen organizar reuniones individuales con la dirección de Helius se les anima a contactar directamente a LD Micro. Este evento ofrece una oportunidad para que Helius muestre su enfoque innovador hacia la terapia de neuromodulación y se relacione con posibles inversionistas.
Helius Medical Technologies (NASDAQ: HSDT)는 균형 및 보행 결핍을 위한 치료적 신경 조절 전문 신경 기술 회사로, LD Micro Invitational XIII 2023에 참여한다고 발표했습니다. 이 행사는 캘리포니아의 Luxe Sunset Boulevard Hotel에서 열릴 예정입니다.
사장 겸 CEO Dane Andreeff와 CFO Jeff Mathiesen가 회의에서 Helius를 대표할 것입니다. 그들의 발표는 2023년 6월 7일 수요일, 오후 4시 PT로 예정되어 있습니다. 관심 있는 분들은 제공된 링크를 통해 웹캐스트에 접속할 수 있습니다.
Helius 경영진과 일대일 미팅을 원하시는 투자자 및 참석자들은 LD Micro에 직접 연락하시기 바랍니다. 이 행사는 Helius가 신경 조절 치료에 대한 혁신적인 접근 방식을 선보이고 잠재적 투자자와 소통할 수 있는 기회를 제공합니다.
Helius Medical Technologies (NASDAQ: HSDT), une entreprise de neurotechnologie spécialisée dans la neuromodulation thérapeutique pour les déficits d'équilibre et de marche, a annoncé sa participation à la LD Micro Invitational XIII 2023. L'événement se déroulera à l'Hôtel Luxe Sunset Boulevard en Californie.
Le président et PDG Dane Andreeff, avec le CFO Jeff Mathiesen, représentera Helius lors de la conférence. Leur présentation est prévue pour le mercredi 7 juin 2023, à 16h00 PT. Les parties intéressées peuvent accéder au webinaire via le lien fourni.
Les investisseurs et participants souhaitant organiser des réunions individuelles avec la direction de Helius sont encouragés à contacter directement LD Micro. Cet événement offre à Helius une occasion de présenter son approche innovante de la thérapie de neuromodulation et d'interagir avec de potentiels investisseurs.
Helius Medical Technologies (NASDAQ: HSDT), ein Neurotechnologieunternehmen, das sich auf therapeutische Neuromodulation bei Gleichgewichts- und Gangstörungen spezialisiert hat, hat seine Teilnahme am LD Micro Invitational XIII 2023 angekündigt. Die Veranstaltung findet im Luxe Sunset Boulevard Hotel in Kalifornien statt.
Präsident und CEO Dane Andreeff sowie CFO Jeff Mathiesen werden Helius auf der Konferenz vertreten. Ihre Präsentation ist für Mittwoch, den 7. Juni 2023, um 16:00 Uhr PT angesetzt. Interessierte Parteien können über den bereitgestellten Link auf das Webcast zugreifen.
Investoren und Teilnehmer, die einzelne Meetings mit dem Management von Helius arrangieren möchten, werden ermutigt, LD Micro direkt zu kontaktieren. Diese Veranstaltung bietet Helius die Möglichkeit, ihren innovativen Ansatz zur Neuromodulationstherapie zu präsentieren und mit potenziellen Investoren zu interagieren.
- None.
- None.
Newtown, Pennsylvania--(Newsfile Corp. - May 25, 2023) - Helius Medical Technologies, Inc. (NASDAQ: HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at LD Micro Invitational XIII 2023, at the Luxe Sunset Boulevard Hotel, California, as follows:
Date: Wednesday, June 7, 2023
Time: 4:00 PM PT
Webcast: Click here
Investors and attendees who would like to schedule a 1-on-1 meeting with Helius management are asked to contact LD Micro.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain's ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis ("MS") and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
PoNS is also authorized for sale in Canada for three indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury ("mmTBI") and is to be used in conjunction with physical therapy; and (ii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke, to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit www.ponstherapy.com.
Investor Relations Contact
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/167368
FAQ
When and where is Helius Medical Technologies (HSDT) presenting at the LD Micro Invitational XIII 2023?
Who will be representing Helius Medical Technologies (HSDT) at the LD Micro Invitational XIII 2023?
How can investors attend Helius Medical Technologies' (HSDT) presentation at the LD Micro Invitational XIII 2023?
What is the focus of Helius Medical Technologies (HSDT) as mentioned in the press release?
